Literature DB >> 30291372

[Therapeutic options in juvenile idiopathic arthritis : Part 1: Nonsurgical treatment].

J-P Haas1, M Arbogast2.   

Abstract

The treatment of children and adolescents with juvenile idiopathic arthritis (JIA) has progressed substantially during recent years. Multiple different factors have played a role in this advancement: improved medical treatment due to the introduction of new drugs, structural improvements with provision of units specializing in childhood rheumatology, multidisciplinary treatment concepts, structured educational programs for patients and parents, improved functional treatment including sports therapy, and selective surgical and orthopedic interventions improving functional capacities. Current treatment strategies in JIA are aimed at achieving disease remission, i.e., control of disease activity and re-establishment of age-appropriate functional capacities. This review summarizes important developments in the conservative treatment of JIA. Part 2 deals with orthopedic and surgical treatment strategies.

Entities:  

Keywords:  Adolescent health; Antirheumatic agents; Biologics; Transition to adult care; Uveitis, anterior

Mesh:

Substances:

Year:  2018        PMID: 30291372     DOI: 10.1007/s00132-018-3645-1

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  26 in total

Review 1.  The psychosocial well-being of children with chronic disease, their parents and siblings: an overview of the research evidence base.

Authors:  J H Barlow; D R Ellard
Journal:  Child Care Health Dev       Date:  2006-01       Impact factor: 2.508

2.  [Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of Paediatric Rheumatology].

Authors:  G Dueckers; N Guellac; M Arbogast; G Dannecker; I Foeldvari; M Frosch; G Ganser; A Heiligenhaus; G Horneff; A Illhardt; R Krauspe; B Markus; H Michels; M Schneider; W Singendonk; H Sitter; M Spamer; N Wagner; T Niehues
Journal:  Klin Padiatr       Date:  2011-10-19       Impact factor: 1.349

3.  Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.

Authors:  R E Petty; T R Southwood; J Baum; E Bhettay; D N Glass; P Manners; J Maldonado-Cocco; M Suarez-Almazor; J Orozco-Alcala; A M Prieur
Journal:  J Rheumatol       Date:  1998-10       Impact factor: 4.666

4.  An urge for change: transitional care for young adults with juvenile idiopathic arthritis.

Authors:  Judy W Ammerlaan; Lieske W Scholtus; Hans J W J Bijlsma; Berent J Prakken; Aike A Kruize
Journal:  Patient Educ Couns       Date:  2013-03-13

5.  Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis.

Authors:  Gregor Dueckers; Nihal Guellac; Martin Arbogast; Guenther Dannecker; Ivan Foeldvari; Michael Frosch; Gerd Ganser; Arnd Heiligenhaus; Gerd Horneff; Arnold Illhardt; Ina Kopp; Ruediger Krauspe; Barbara Markus; Hartmut Michels; Matthias Schneider; Wolfram Singendonk; Helmut Sitter; Marianne Spamer; Norbert Wagner; Tim Niehues
Journal:  Clin Immunol       Date:  2011-10-26       Impact factor: 3.969

6.  Evaluation of the ILAR criteria for juvenile idiopathic arthritis.

Authors:  M Krumrey-Langkammerer; R Häfner
Journal:  J Rheumatol       Date:  2001-11       Impact factor: 4.666

7.  Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study.

Authors:  H Truckenbrodt; R Häfner
Journal:  Arthritis Rheum       Date:  1986-06

8.  Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.

Authors:  Leigh D Church; Michael F McDermott
Journal:  Curr Opin Mol Ther       Date:  2009-02

9.  Treatment preferences in juvenile idiopathic arthritis - a comparative analysis in two health care systems.

Authors:  Boris Hugle; Johannes-Peter Haas; Susanne M Benseler
Journal:  Pediatr Rheumatol Online J       Date:  2013-01-15       Impact factor: 3.054

Review 10.  Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors:  V Boom; J Anton; P Lahdenne; P Quartier; A Ravelli; N M Wulffraat; S J Vastert
Journal:  Pediatr Rheumatol Online J       Date:  2015-12-03       Impact factor: 3.054

View more
  2 in total

1.  [Clinical characteristics and biological treatment of adult patient with juvenile idiopathic arthritis].

Authors:  S X Wei; S J Li; Y Liu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

Review 2.  [Rheumatic pain and chronic pain in children, adolescents and young adults].

Authors:  L Höfel; N Draheim; A Schramm; M Georgi; J P Haas
Journal:  Z Rheumatol       Date:  2021-01-08       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.